1 available, 1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Balstililmab: new trials by email Literature Review of Balstililmab trials Research Report on Balstililmab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease. Gemcitabine (1000 mg/m2), Nab-paclitaxel (Abraxane), NLM-001 - Untreated, Advanced Pancreatic Cancer | Phase 2 | Not yet recruiting | Nelum Corp | 40 | 2026-07-15 | 2026-05-13 |
| Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval Botensilimab, Balstililmab - Colorectal Cancer (CRC), Pancreatic Cancer | Available | Agenus Inc. | 2026-05-15 |
Pancreatic Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Sarcoma (1)
Agenus Inc. (1) · Nelum Corp (1)
Spain (1)